Countouriotis Athena
SEC-identified person · CIK 1571469 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Lion Biotechnologies, Inc. N/A | Director | filed 2019 - 2026 |
| Biomarin Pharmaceutical INC BMRN | Director | filed 2023 - 2026 |
| Passage BIO, Inc. PASG | Director | filed 2020 - 2026 |
| Turning Point Therapeutics, Inc. TPTX | Director · President & CEO | filed 2019 - 2022 |
| Xenomics INC XNOM.PK | Director | filed 2017 - 2019 |
| Avalanche Biotechnologies, Inc. [AAVL] | SVP, Chief Medical Officer | filed 2017 - 2018 |
| Halozyme Therapeutics, INC. Halo | SVP and Chief Medical Officer | filed 2015 - 2017 |
| Ambit Biosciences Corp AMBI | Chief Medical Officer | filed 2013 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.